Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 82 5-Year Yield-on-Cost % is 0.66 as of Jul. 14, 2026, which is at its 10-year median of 0.66. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €208.01 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 84.4% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:DIMp'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14 Med: 0.66 Max: 1.63
Current: 0.66
During the past 13 years, Sartorius Stedim Biotech's highest Yield on Cost was 1.63. The lowest was 0.14. And the median was 0.66.
CHIX:DIMp's 5-Year Yield-on-Cost % is ranked worse than 84.4% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.33
vs CHIX:DIMp: 0.66
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sartorius Stedim Biotech 5-Year Yield-on-Cost % Related Terms
CHIX:DIMP vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sartorius Stedim Biotech (CHIX:DIMP) has a 5-Year Yield-on-Cost % of 0.66 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sartorius Stedim Biotech and its competitors. This is near median its historical median of 0.66. Over the past decade, Sartorius Stedim Biotech's 5-Year Yield-on-Cost % has ranged from 0.14 to 1.63. According to the industry distribution chart, Sartorius Stedim Biotech ranks #276 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 84.4%.
Is Sartorius Stedim Biotech's 5-Year Yield-on-Cost % too high?
Sartorius Stedim Biotech's current 5-Year Yield-on-Cost % of 0.66 is near median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.63. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.33. Sartorius Stedim Biotech's value of 0.66 is 71.7% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #276 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #276 out of 327 companies for 5-Year Yield-on-Cost %. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Sartorius Stedim Biotech's value of 0.66 is 71.7% below this benchmark. Historically, Sartorius Stedim Biotech's own 5-Year Yield-on-Cost % has ranged from 0.14 to 1.63 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 2.33, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current 5-Year Yield-on-Cost % of 0.66 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current 5-Year Yield-on-Cost % is 0.66, which is near median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €208.01, compared to a current price of €179.05 — trading 13.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.66, which is near median its 10-year median of 0.66 and 71.7% below the Medical Devices & Instruments industry median of 2.33. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current 5-Year Yield-on-Cost % is 0.66 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €179.05 is trading 13.9% below its estimated GF Value™ of €208.01.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
5-Year Yield-on-Cost %: 0.66 (near median its 10-year median of 0.66)
GF Value™: €208.01 vs. price of €179.05 (13.9% below fair value)
Industry Position: 71.7% below the Medical Devices & Instruments median (#276 of 327)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
